

ASH CLINICAL PRACTICE GUIDELINES VENOUS THROMBOEMBOLISM (VTE)



Prophylaxis for Hospitalized and Non-Hospitalized Medical Patients

An Educational Slide Set

American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism

Slide set authors: Eric Tseng MD MScCH, University of Toronto Mary Cushman MD MSc, University of Vermont



American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and non-hospitalized medical patients

Holger J. Schünemann, Mary Cushman, Allison E. Burnett, Susan R. Kahn, Jan Beyer-Westendorf, Frederick A. Spencer, Suely M. Rezende, Neil A. Zakai, Kenneth A. Bauer, Francesco Dentali, Jill Lansing, Sara Balduzzi, Andrea Darzi, Gian Paolo Morgano, Ignacio Neumann, Robby Nieuwlaat, Juan J. Yepes-Nuñez, Yuan Zhang, and Wojtek Wiercioch

CLINICAL GUIDEL	INES	Solo advances
		<u> </u>
	ety of Hematology 2018 guidelines oembolism: prophylaxis for hosp	
	d medical patients	Italizeu allu
nonnospitanze	a mealear patients	
Suely M. Rezende, ⁹ Neil A.	Mary Cushman, ^{3,4,*} Allison E. Burnett, ⁵ Susan R. Kahn, ⁶ Jan Br Zakaj, ^{3,4} Kenneth A. Bauer, ¹⁰ Francesco Dentali, ¹¹ Jill Lansing, io Neumann, ^{2,14} Robby Nieuwlaat, ² Juan J. Yepes-Nuñez, ² Yu	¹² Sara Balduzzi, ¹³ Andrea Darzi, ²
⁴ Department of Pathology and Lab Antithrombosis Service, University QC, Carada; ⁷ Thrombosis Resear Service, Department of Hematolog Belo Horicotte, Minas Gerais, Brazi Surgery, Insubria University, Vareee	Interest of Health Research Merkolas, Esidence and Ingest, McMateur Ulowing and Medicine, Ulowardy of Warnets Lance ("Chiling of Medicine and Ulawinets New Merko's Nethalth Sciences Centre, Albacyuran, NA, "Department of Medicine ULO, Unioni of Healthangiko, Dipatienteri of Merkoline, U biawaity Hospital" Carl Kriego Collega London, Unied Kriegolam, "Department of Internet Medicine, Tex- Trogenomical Medicine, Bells Imana Descourse Medical Center, Hennes Medi- Hag", "Based Londons, Bells Imana Descourse Medical Center, Hennes Medi- Hag", "Based Londons, Other Work, Adamy, NY, "Conctens table, Department Internet Medicine, Science J Medican, School of Medican, Editor, Based Center, Science J Medican, Editor, Based Center, Science J Medican, Editor, School of Medican, School	rol Varmont Medical Center, Burlington, VT; ⁶ Inpatient ne, McGell Uriversity and Lady Davis Institute, Montreal, Gestav Carue, ⁷ Deeden, Germany, ⁷ Kings Thrombosis ity of Medicine, Universiteder Federal de Manas Gensis, cal School, Boston, MA; ¹¹ Department of Medicine and O Diagnostic, Circial and Public Health Medicine,
	Background: Venous thromboembolism (VTE) is the third long-term care residents, persons with minor injuries, and k	
	Objective: These evidence-based guidelines from the to support patients, clinicians, and others in decisions a	
	Methods: ASH formed a multidisciplinary guideline p conflicts of interest. The McMaster University GRADE process, including updating or performing systematic questions and outcomes according to their importance Recommendations Assessment, Development and Eval and make recommendations, which were subject to put	Centre supported the guideline-developmer evidence reviews. The panel prioritized clinic for clinicians and adult patients. The Grading of uation approach was used to assess evidence
	Results: The panel agreed on 19 recommendations for people in long-term care facilities, outpatients with mind	
	Conclusions: Strong recommendations included pro- actuety or crinically ill inpaints at acceptable bleed bleeding risk is unacceptable, against the use of direct against structuring pharmacobicgial prophylaxis after hor included not to use VIE prophylaxis routinely in long- tid factors. The parel conditionally included us melecular-weight heparin in borg-distance travelers only	ng risk, use of mechanical prophytaxis whe oral anticoagulants during hospitalization, an spital discharge. Conditional recommendation m care patients or outpatients with minor VT e of graduated compression stockings or low
	Summary of recommendations	
	Background	
	Venous thromboembolism (VTE) is the third most comm rate of ~1 in 1000 annually in middle age and increasing 50% of all VTE events occur as a result of a current or	to nearly 1% annually in nonagenarians.1 About

Submitted 27 June 2018; accepted 19 September 2018. DOI 10.1182/ bloodadvances.2018022954. *HJS. and M.C. are joint finst authors. Resources for implementing these guidelines, including apps, patient decision aids,

27 NOVEMBER 2018 · VOLUME 2, NUMBER 2

The full-text version of this article contains a data supple © 2018 by The American Society of Hematology





- 1. Prevention of VTE in Surgical Hospitalized Patients
- 2. Prophylaxis in Hospitalized and Non-Hospitalized Medical Patients
- 3. Treatment of Acute VTE (DVT and PE)
- 4. Optimal Management of Anticoagulation Therapy
- 5. Prevention and Treatment of VTE in Patients with Cancer
- 6. Heparin-Induced Thrombocytopenia (HIT)
- 7. Thrombophilia
- 8. Pediatric VTE
- 9. VTE in the Context of Pregnancy
- 10. Diagnosis of VTE





How were these ASH guidelines developed?

PANEL FORMATION

Each guideline panel was formed following these key criteria:

- Balance of expertise (including disciplines beyond hematology, and patients)
- Close attention to minimization and management of COI

CLINICAL QUESTIONS

10 to 20 clinicallyrelevant questions generated in PICO format (population, intervention, comparison, outcome)

Example: PICO question "Should LMWH versus UFH be used for VTE prophylaxis in critically ill patients?"

EVIDENCE SYNTHESIS

Evidence summary generated for each PICO question via systematic review of health effects plus:

- Resource use
- Feasibility
- Acceptability
- Equity
- Patient values and preferences

MAKING RECOMMENDATIONS

Recommendations made by guideline panel members based on evidence for all factors.

ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources, such as this slide set, derived from guidelines that require updating are removed from the ASH website.



How patients and clinicians should use these recommendations

	STRONG Recommendation ("The panel recommends")	CONDITIONAL Recommendation ("The panel suggests")
For patients	Most individuals would want the intervention.	A majority would want the intervention, but many would not.
For clinicians	Most individuals should receive the intervention.	Different choices will be appropriate for different patients, depending on their values and preferences. Use shared decision making .





Half of VTE events occur due to hospital admission for surgery (24%) or medical illness (22%) **Risk factors for VTE in hospital** include cancer, older age, prior VTE, central lines, immobility

40% of hospitalized patients have 3 or more risk factors for VTE Increase in thrombosis risk in medical inpatients persists **45 to 60 days** after discharge



Patient groups addressed in this chapter



Acutely III Medical Patient Patients hospitalized for medical illness



Critically III Patient Patients suffering from immediately lifethreatening illness requiring admission to intensive care unit



Chronically III Medical Patient

Those with medical conditions who may be cared for in long-term care facilities



Long-distance Traveler Those traveling by air for ≥ 4 hours



Who is at risk for VTE in hospital?

- Risk Assessment Models (RAMs) can identify inpatients at high risk
- **Examples:** Padua, IMPROVE-VTE Scores

These RAMs are not extensively validated for guiding decisions about prophylaxis

Padua RAM: Factors

Previous VTE Thrombophilia Active cancer Age > 70 years Reduced mobility Recent trauma/surgery Heart or respiratory failure Acute MI or stroke Hormonal treatment Obesity (BMI > 30) Infection/rheumatologic

IMPROVE-VTE RAM: Factors

Previous VTE Thrombophilia Active cancer Age > 60 years Immobilization of ≥ 7 days Lower limb paralysis ICU/CCU stay

> Spyropoulos Chest 2011 Leizorovicz Circulation 2004



The following outcomes were rated by the panel as critical to decision-making:

- High value was placed on avoiding these outcomes
- Asymptomatic VTE were not considered critical outcomes

Mortality Pulmonary Embolism (PE) Moderate to Severe Deep Vein Thrombosis (DVT) Major Bleeding





Case: Medical Inpatient Admission

82 year old male

Past Medical History: Emphysema, type 2 diabetes, obesity (body mass index [BMI] of 42 kg/m²), provoked DVT 15 years ago (after appendectomy)

Medications: Tiotropium, metformin, amlodipine, ramipril

Admitted to: Internal Medicine Ward with pneumonia

Treated with: antibiotics, supplemental oxygen

He is not ambulating on the ward due to dyspnea and generalized weakness.






- A. Subcutaneous low molecular weight heparin (LMWH)
- B. Direct oral anticoagulant (Betrixaban, Rivaroxaban, or Apixaban)
- C. Graduated compression stockings
- D. No prophylaxis because patient is low thrombosis risk











- In acutely ill medical patients, the panel suggests using <u>UFH, LMWH, or fondaparinux</u> rather than no parenteral anticoagulant (conditional recommendation, low certainty)
- The panel suggests using LMWH (low certainty) or fondaparinux (very low certainty) rather than UFH (conditional recommendation)

Outcomes	Relative effect: RR (95% Cl)	Anticipated absolute effects (95% CI)		
		Risk with no parenteral anticoagulant	Risk difference with parenteral anticoagulant	
Mortality	0.97 (0.91 to 1.04)	69 per 1,000	2 fewer deaths per 1,000 (6 fewer to 3 more)	
e pe	0.59 (0.45 to 0.78)	10 per 1,000	4 fewer PE per 1,000 (6 fewer to 2 fewer)	
 Symptomatic proximal DVT 	0.28 (0.06 to 1.37)	4 per 1,000	3 fewer DVT per 1,000 (4 fewer to 1 more)	
Major bleeding	1.48 (0.81 to 2.71)	7 per 1,000	3 more bleeds per 1,000 (1 fewer to 12 more)	

Parenteral anticoagulant compared with no parenteral anticoagulant:





Recommendation

In acutely or critically ill medical patients, the panel suggests using pharmacological VTE prophylaxis over mechanical prophylaxis (conditional recommendation, very low certainty)

Pharmacologic prophylaxis compared with mechanical prophylaxis

(graduated compression stockings or pneumatic compression devices):

Outcomes	Relative effect: RR (95% Cl)	Anticipated absolute effects (95% CI)		
		Risk with pharmacologic prophylaxis	Risk difference with mechanical prophylaxis	
 Mortality 	0.95 (0.42 to 1.13)	18 per 1,000	1 fewer death per 1,000 (11 fewer to 21 more)	
• PE	1.54 (0.48 to 4.93)	1 per 1,000	1 more PE per 1,000 (1 fewer to 4 more)	
 Symptomatic proximal DVT 	2.20 (0.22 to 22.09)	2 per 1,000	2 more DVT per 1,000 (1 fewer to 38 more)	
• Major bleeding	0.87 (0.25 to 3.08)	28 per 1,000	4 fewer bleeds per 1,000 (21 fewer to 58 more)	





In acutely ill hospitalized **medical patients**, the panel recommends using **LMWH over DOACs** for VTE prophylaxis (strong recommendation, moderate certainty)

	Relative effect:	Anticipated absolute effects (95% CI)	
Outcomes	RR (95% CI)	Risk with prophylactic LMWH	Risk difference with any DOAC
Mortality	0.64 (0.21 to 1.98)	1 per 1,000	0 fewer deaths per 1,000 (1 fewer to 1 more)
PE	1.01 (0.29 to 3.53)	1 per 1,000	0 fewer PE per 1,000 (1 fewer to 3 more)
Symptomatic proximal DVT	1.03 (0.34 to 3.08)	2 per 1,000	0 fewer DVT per 1,000 (1 fewer to 4 more)
Major bleeding	1.70 (1.02 to 2.82)	2 per 1,000	2 more bleeds per 1,000 (0 fewer to 4 more)*

Any DOAC compared with prophylactic LMWH:

stimates OW risk



You start VTE prophylaxis with **prophylactic LMWH** for this internal medicine admission

Two days into the hospital admission, your patient is admitted to the **critical care unit** with respiratory failure and septic shock

- He is intubated and started on vasopressors
- His labs:

Labs on Transfer to ICU

Hemoglobin	12.0 g/dL
Platelets	103 x 10 ^{9/} L
Leukocytes	15.6 x 10 ^{9/} L
Creatinine	1.47 mg/dL (eGFR 49 mL/min/1.73 m ²)





Your patient has been transferred to the intensive care unit (ICU), and has mild thrombocytopenia and acute kidney injury.

Which ONE of the following options would you recommend for thromboprophylaxis now?

- A. Subcutaneous LMWH
- B. Subcutaneous Unfractionated Heparin (UFH)
- C. Graduated Compression Stockings
- D. Graduated Compression Stockings combined with LMWH





In **critically ill medical patients**, the panel suggests using **LMWH over UFH** (conditional recommendation, moderate certainty)

LMWH compared with **UFH** in critically ill patients:

Outrouver	Relative effect:	Anticipated absolute effects (95% CI)	
Outcomes	RR (95% CI)	Risk with UFH	Risk difference with LMWH
Mortality	0.90 (0.75 to 1.08)	243 per 1,000	24 fewer deaths per 1,000 (61 fewer to 19 more)
PE	0.80 (0.44 to 1.46)	11 per 1,000	2 fewer PE per 1,000 (6 fewer to 5 more)
Symptomatic proximal DVT	0.87 (0.60 to 1.25)	25 per 1,000	3 fewer DVT per 1,000 (10 fewer to 6 more)
Major bleeding	0.98 (0.76 to 1.27)	53 per 1,000	1 fewer bleeds per 1,000 (13 fewer to 14 more)
Heparin-induced thrombocytopenia	0.42 (0.15 to 1.18)	6 per 1,000	4 fewer episodes per 1,000 (5 fewer to 1 more)

Critically ill patients may require other prophylaxis options due to hepatic or renal dysfunction.

Quality of Evidence (GRADE): Low 🛑 Moderate 🛑 Strong 🛑





Recommendation

In **acutely and critically ill medical patients**, the panel **suggests pharmacological VTE prophylaxis alone** over mechanical combined with pharmacological VTE prophylaxis (conditional recommendation, very low certainty)

Mechanical combined with pharmacologic compared with pharmacologic alone:

Outcomes	Relative effect: RR (95% CI)	Anticipated absolute effects (95% CI)		
		Risk with pharmacologic prophylaxis alone	Risk difference with combined prophylaxis	
 Mortality 	0.50 (0.05 to 5.30)	8 per 1,000	4 fewer deaths per 1,000 (8 fewer to 34 more)	
PE	0.35 (0.05 to 2.22)	1 per 1,000	1 fewer PE per 1,000 (1 fewer to 1 more)	
 Symptomatic proximal DVT 	0.13 (0.04 to 0.40)	2 per 1,000	2 fewer DVT per 1,000 (2 fewer to 1 fewer)	
Major bleeding	2.83 (0.30 to 26.70)	28 per 1,000	51 more bleeds per 1,000 (20 fewer to 720 more)	




Case: Back to our patient

- You decide to continue prophylactic LMWH without mechanical prophylaxis after your patient's transfer to the ICU
- Three days into his ICU admission, he develops **upper GI bleeding**
- Gastroscopy reveals a small gastric ulcer with a visible bleeding vessel; this vessel is clipped

Hemoglobin	7.5 g/dL
Platelets	88 x 10 ^{9/} L
Leukocytes	13.0 x 10 ^{9/} L
Creatinine	1.47 mg/dL (eGFR 49 mL/min/1.73 m ²)





Which of the following options for thromboprophylaxis would you suggest at this time?

- A. Graduated Compression Stockings
- B. Pneumatic Compression Devices
- C. Calf exercises
- D. No mechanical prophylaxis is needed





In **acutely and critically ill medical patients** who are not receiving pharmacological VTE prophylaxis, the panel suggests **either pneumatic compression devices or graduated compression stockings** for VTE prophylaxis (conditional recommendation, very low certainty)

Outcomes	Relative effect: RR (95% CI)	Anticipated absolute effects (95% CI)		
		Risk with graduated compression stockings	Risk difference with pneumatic compression	
 Mortality 	3.43 (0.15 to 79.74)	0 per 1,000	0 fewer deaths per 1,000 (0 fewer to 0 fewer)	
PE	0.38 (0.02 to 8.86)	43 per 1,000	27 fewer PE per 1,000 (43 fewer to 342 more)	
Symptomatic proximal DVT	0.16 (0.01 to 2.98)	130 per 1,000	110 fewer DVT per 1,000 (129 fewer to 258 more)	

Pneumatic compression devices compared with graduated compression stockings:





Case continued: Discharge from hospital

- Your patient recovers from his upper GI bleed and septic shock, and is transferred back to the internal medicine ward.
- Within a few days he is started back on LMWH for pharmacologic VTE prophylaxis.
- He has been in hospital for a total of 9 days and is being discharged back to his home, as his pneumonia has resolved.



You are discharging your patient after an acute medical illness. He has received prophylaxis with LMWH in hospital for 9 days. He is ambulatory and back on his usual medications.

What would you recommend on discharge for VTE prophylaxis?

- A. Stop LMWH on the day of discharge
- B. Extend LMWH for 3 weeks post-discharge
- C. Switch LMWH on discharge to a DOAC, and continue the DOAC for 3 weeks post-discharge
- D. Graduated compression stockings for 3 weeks post-discharge





What is the rationale for extending VTE prophylaxis beyond hospital discharge?

- Most hospital-related VTE events occur **out of hospital**, in the first month after discharge
- VTE risk in medical patients is elevated for 45-60 days post-discharge
- Duration of inpatient prophylaxis is shortening as the average hospital length of stay decreases

Huang Am J Med 2014 Cohen NEJM 2016 Cohen NEJM 2014 Goldhaber NEJM 2011





In acutely ill hospitalized medical patients, the panel recommends **inpatient over inpatient plus extended duration outpatient VTE prophylaxis** (strong recommendation, moderate certainty).

Extended prophylaxis (30-40 days) compared with in-hospital prophylaxis (any agent):

	Relative effect:	Anticipated absolute effects (95% CI)	
Outcomes	RR (95% CI)	Risk difference with extended prophylaxis	
Mortality	1.00 (0.89 to 1.12)	0 fewer deaths per 1,000 (5 fewer to 5 fewer)	
PE	0.63 (0.39 to 1.03)	1 fewer PE per 1,000 (3 fewer to 0 fewer)	
Symptomatic proximal DVT	0.54 (0.32 to 0.91)	3 fewer DVT per 1,000 (4 fewer to 1 fewer)	
Major bleeding	2.09 (1.33 to 3.27)	4 more bleeds per 1,000 (1 more to 8 more)	





In acutely ill hospitalized medical patients, the panel recommends **inpatient VTE prophylaxis with LMWH only**, rather than inpatient and extended duration outpatient VTE prophylaxis with DOACs (strong recommendation, moderate certainty)

Extended DOAC prophylaxis (30-40 days) compared with shorter LMWH prophylaxis:

Outcomes	Relative effect: RR (95% CI)	Anticipated absolute effects (95% CI)		
		Risk with shorter duration non- DOAC inpatient prophylaxis	Risk difference with extended prophylaxis with DOAC	
 Mortality 	1.01 (0.89 to 1.14)	49 per 1,000	0 fewer deaths per 1,000 (5 fewer to 7 more)	
e PE	0.67 (0.41 to 1.09)	4 per 1,000	1 fewer PE per 1,000 (2 fewer to 0 fewer)	
Symptomatic proximal DVT	0.62 (0.36 to 1.05)	6 per 1,000	2 fewer DVT per 1,000 (4 fewer to 0 fewer)	
Major bleeding	1.99 (1.08 to 3.65)	4 per 1,000	4 more bleeds per 1,000 (0 more to 10 more)	





In summary, why is routine post-discharge extended prophylaxis currently not recommended?

- Extended prophylaxis *may* reduce PE and DVT, but <u>absolute impact on VTE reduction is very small</u> (1 to 3 fewer VTE per 1,000 patients treated), and is similar to number of bleeding events caused
- Extended prophylaxis does not impact mortality
- Possible that the three included RCTs (APEX, MAGELLAN, ADOPT) did not select patients at sufficiently high risk for VTE
 - However, the recent MARINER trial (Spyropoulos NEJM 2018) also did not show significant reduction in VTE despite use of a modified IMPROVE VTE risk score to select high-risk medical inpatients for extended prophylaxis with rivaroxaban





Case Conclusion and a Visitor

- On discharge you stop LMWH, and he does not receive extended VTE prophylaxis out of hospital. He recovers and does not develop VTE.
- Two months later, the patient's 50 year old niece decides to visit him from England (7 hour flight to Baltimore).
- She is has a history of unprovoked DVT 4 years ago, and her BMI is 38 kg/m². She is currently not on anticoagulant or antiplatelet therapy.



This patient's niece has a history of unprovoked VTE, and her BMI is 38. She is boarding a long-distance flight (> 4 hours).

What would you suggest for VTE prophylaxis during her flight?

A. LMWH

- B. Graduated compression stockings
- C. Aspirin
- D. No prophylaxis is needed



Air Travel and VTE

- Long-distance travelers: 4-hour flight or longer
- Air travel associated with 2.8-fold increase in risk of VTE; risk increases with flight duration
- Several risk factors increase risk of VTE multiplicatively with risk of prolonged air travel
 - Pregnancy, cancer, plaster casts, hormonal therapy, oral contraception





- In people at increased VTE risk the panel suggests using graduated compression stockings or prophylactic LMWH for long-distance travel (conditional recommendation, very low certainty)
- If compression stockings or LMWH are not used, aspirin should be used instead of no prophylaxis (conditional recommendation, very low certainty)

Who is at increased risk?

- Recent surgery
- Prior VTE
- Postpartum women
- Active malignancy
- 2+ risk factors including combinations of the above with hormonal replacement therapy, obesity, or pregnancy

- LMWH, stockings, and ASA have small, uncertain benefit
- There is no evidence regarding use of DOACs for prophylaxis during air travel





Stockings, LMWH, and aspirin have small, very uncertain effects on VTE prevention – and the estimated absolute benefits are very small

Intervention	Relative Effects (RR, 95% CI) on VTE Prevention (<i>compared</i> <i>with no intervention</i>)	Absolute Risk Difference with each intervention (compared with no prophylaxis)
Graduated Compression Stockings	0.10 (0.04 to 0.25)	 3 fewer PE per 1,000,000 (3 fewer to 3 fewer) 1.8 fewer asymptomatic DVT per 10,000 (1.9 fewer to 1.5 fewer)
LMWH	0.10 (0.10 to 2.11)	 3 fewer PE per 1,000,000 (3 fewer to 4 more) 17.8 fewer asymptomatic DVT per 10,000 (1.9 fewer to 2.2 more)
Aspirin	0.75 (0.13 to 4.32)	 1 fewer PE per 1,000,000 (3 fewer to 12 more) 0.5 fewer asymptomatic DVT per 10,000 (1.7 fewer to 6.5 more)





Applying these guidelines to our patient: why are these recommendations "conditional?"

50 year old fema

What is her approxima Baseline annual risk ≈ 1 Daily VTE risk ≈ 1 in 100 VTE risk per flight ≈ 1 in

What is the benefit of RR 0.10 (95% CI 0.01-2

There is very low certainty and small absolute effect size in these estimates

Physicians must take patient-centered factors into account

Approximate VTE risk per flight with LMWH = 3% x 0.10 = 0.3% (high uncertainty, 95% CI 0.03% to 6.3%)





However, patients without VTE risk factors do not merit prophylaxis for air travel

Recommendation

In long-distance travelers **without risk factors for VTE**, the panel suggests **not using graduated compression stockings, LMWH, or aspirin** for VTE prophylaxis (conditional recommendation, very low certainty)



Case: Conclusion

- Given her history of previous VTE and obesity, you feel that she merits VTE prophylaxis either with graduated compression stockings or LMWH during her flight.
- She receives prophylactic LMWH on the morning of her 7-hour flight, and does not develop VTE.





Other guideline recommendations that were not covered in this presentation

For these topics, conditional recommendations were made based on weak or very weak quality of evidence

- Medical outpatients with **minor provoking risk factors** for VTE (immobility, minor injury, illness, infection)
- Chronically ill medical patients or nursing home patients



Some of the 29 identified future priorities for research

- Optimal prophylaxis dosing for obese, underweight, renal patients
- Utility of mechanical prophylaxis in medical outpatients at high risk
- Bleeding and thrombosis risk estimation in medical and critically ill patients
- More study of post discharge measures to prevent VTE
- Comparison of different forms of mechanical prophylaxis to each other
- Comparison of combined approaches (mechanical plus pharmacologic) versus pharmacologic prophylaxis alone
- Utility of prophylaxis in high-risk chronically ill/nursing home patients
- Effectiveness and safety of DOACs for prophylaxis during air travel





In Summary: Back to our Objectives

- 1. Describe VTE prophylaxis recommendations for patients hospitalized with a **medical illness** or **critical illness**
 - Risk assessment models, LMWH compared with DOACs
- 2. Describe VTE prophylaxis recommendations for patients **discharged from hospital** after an acute medical illness
 - Extended versus in-hospital prophylaxis, LMWH compared with DOACs
- 3. Identify when **long-distance travelers** may benefit from receiving VTE prophylaxis
 - Graduated compression stockings or LMWH for those with strong VTE risk factors



Acknowledgements

- ASH Guideline Panel team members
- Knowledge Synthesis team members
- McMaster University GRADE Centre
- Author of ASH VTE Slide Sets: Eric Tseng MD MScCH, University of Toronto and Mary Cushman MD MSc, University of Vermont

See more about the ASH VTE guidelines at www.hematology.org/vte